drugset / Trial / NCT01038921

Melatonin and the Metabolic Syndrome

NCT01038921

Phase 2 Completed 39 enrolled Emory University
RandomizedCrossoverDouble-blindTreatment

Summary

This trial seeks to compare the effects of melatonin supplementation versus placebo in subjects with the metabolic syndrome.

Timeline

Start
2009-07
Primary completion
2012-06
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Melatonin Small molecule 8 mg Oral

Indications